Dominant pharmacy benefit managers (PBMs) are hiking the cost of drugs and squeezing independent pharmacies that many Americans depend on for essential care, according to a Federal Trade Commission (FTC) interim report released on July 9.
The report examined the roles PBMs play in the pharmaceutical supply chain, highlighting their impact on drug prices, access to medications, and the viability of independent pharmacies.
